NASDAQ · FRBNU
Forbion European Acquisition Corp.
$20.00-$0.62 (-3.01%)
Forbion European Acquisition Corp.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
Loading market information…
NASDAQ · EUCR · USD
Stock price, earnings
Quote as of Apr 26, 2023, 07:14 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Eucrates Biomedical Acquisition Corp.’s quoted price sits in the lower half of its reported 52-week range, 2.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eucrates Biomedical Acquisition Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises. Specifically, it aims to find and acquire a company operating within the life sciences or broader healthcare sectors across North America and Europe. Established in 2020, this entity has its headquarters situated in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$20.00-$0.62 (-3.01%)
Forbion European Acquisition Corp.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
$10.53-$0.01 (-0.09%)
The Growth for Good Acquisition Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.39% below the high.
$10.65-$1.08 (-9.21%)
UTA Acquisition Corporation’s quoted price sits in the lower half of its reported 52-week range, 9.36% below the high.
$10.35-$0.01 (-0.1%)
Forum Merger IV Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.48% below the high.
$11.21+$0.46 (+4.28%)
Artemis Strategic Investment Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$11.37+$11.37 (+100.0%)
Target Global Acquisition I Corp.’s quoted price sits in the lower half of its reported 52-week range, 0.09% below the high.
$0.01$0.00 (0.0%)
TKB Critical Technologies 1’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$12.00+$1.21 (+11.21%)
Pono Capital Two, Inc.: Financial Services · Shell Companies.
